Nosrat MADADİ MAHANİ, Alireaza MOHADESİ ZARANDİ, Azra HORZADEH

QSAR studies of novel iminochromene derivatives as carbonyl reductase 1 (CBR1) inhibitors

A quantitative Structure-Activity Relationship (QSAR) model was applied to the prediction of the activity of iminochromene derivatives. The inhibition activity of 34 carbonyl reductase 1 (CBR1) inhibitors were modeled with the descriptors of quantum-chemical calculations with density functional theory (DFT) method at B3LYP/6‒31G level. This study was conducted using the multiple linear regressions (MLR), the partial least square analysis (PLS) and the principal component analysis (PCA) method. Results displayed that the MLR method predicted of activity good enough. The best model, with seven descriptors was selected. Also it indicates very good consistency towards data variations for the validation methods. The predicted values of activities are in suitable agreement with the experimental results. The obtained results suggested that the PCA method could be more helpful to predict the biological activity of iminochromene derivatives. It is anticipated to be useful to predict the activity of other compounds in the same groups.

PDF

___

[1] Hoffmann F, Maser E. Carbonyl reductases and pluripotent hydroxysteroid dehydrogenases of the short-chain dehydrogenase/reductase superfamily. Drug Metab Rev. 2007; 39(1): 87-144.

[2] Oppermann U. Carbonyl reductases: the complex relationships of mammalian carbonyl- and quinone-reducing enzymes and their role in physiology. Annu Rev Pharmacol Toxicol.2007; 47: 293-322.

[3] Malatkova P, Maser E, Wsol V. Human carbonyl reductases. Curr Drug Metab. 2010; 11(8): 639-658.

[4] Wermuth B. Purification and properties of an NADPH-dependent carbonyl reductase from human brain. Relationship to prostaglandin 9-ketoreductase and xenobiotic ketone reductase. J BiolChem. 1981; 256(3):1206-1213.

[5] Tanaka M, Bateman R, Rauh D, Vaisberg E, Ramachandani S, Zhang C, Hansen KC,Burlingame AL, Trautman JK, Shokat KM, Adams CL. An unbiased cell morphology-based screen for new, biologically active small molecules. PLoS Biol.2005; 3(5):128-135.

[6] Zimmermann TJ, Niesen FH, Pilka ES, Knapp S, Oppermann U, Maier ME. Discovery of a potent and selective inhibitor for human carbonyl reductase 1 from propionate scanning applied to the macrolide zearalenone. Bioorg Med Chem. 2009; 17(2):530-536.

[7] Ito Y, Mitani T, Harada N, Isayama A, Tanimori S, Takenaka S, Nakano Y, Inui H, Yamaji R. Identification of carbonyl reductase 1 as a resveratrol-binding protein by affinity chromatography using 4'-amino-3,5-dihydroxy-trans-stilbene. J Nutr Sci Vitaminol. (Tokyo) 2013; 59(4): 358-364.

[8] Huang W, Ding L, Huang Q, Hu H, Liu S, Yang X, Hu X, Dang Y, Shen S, Li J, Ji X, Jiang S, Liu JO, Yu L. Carbonyl reductase 1 as a novel target of (-)-epigallocatechin gallate against hepatocellular carcinoma. Hepatology2010; 52(2):703-714.

[9] Gonzalez-Covarrubias V, Kalabus JL, Blanco JG. Inhibition of polymorphic human carbonyl reductase 1 (CBR1) by the cardioprotectant flavonoid 7-monohydroxyethyl rutoside (monoHER). Pharm Res. 2008; 25(7):1730-1734.

[10] Carlquist M, Frejd T, Gorwa-Grauslund MF. Flavonoids as inhibitors of human carbonyl reductase 1. Chem Biol Interact. 2008; 174(2):98-108.

[11] Hu D, Miyagi N, Arai Y, Oguri T, Miura T, Nishinaka T, Terada T, Gouda H, El-Kabbani O, Xia S, Toyooka N, Hara A, Matsunaga T, Ikari A, Endo S. Synthesis of 8-hydroxy-2-iminochromene derivatives as selective and potent inhibitors of human carbonyl reductase 1. Org Biomol Chem. 2015;13(27): 7487-7499.

[12] Hadjipavlou-Litina D. Review: reevaluation and new results in quantitative structure-activity studies of anticonvulsants. Med Res Rev.1998; 18(2): 91-119.

[13] Gramatica P, Papa E. QSAR modeling of bioconcentration factor by theoretical molecular descriptors. QSAR Comb Sci. 2003; 22(3):374-385.

[14] Hansch C, Kurup A, Garg R, Gao H. Chem-bioinformatics and QSAR: a review of QSAR lacking positive hydrophobic terms. Chem Rev. 2001; 101(3): 619-672.

[15] Agrawal VK, Bano S, Supuran CT, Khadikar PV. QSAR study on carbonic anhydrase inhibitors: aromatic/heterocyclic sulfonamides containing 8-quinoline-sulfonyl moieties, with topical activity as antiglaucoma agents. Eur J Med Chem.2004; 39(7): 593-600.

[16] Kumar R, Son M, Bavi R, Lee Y, Park C, Arulalapperumal V, Cao GP, Kim H, Suh J, Kim Y, Kwon YJ, Lee KW. Novel chemical scaffolds of the tumor marker AKR1B10 inhibitors discovered by 3D QSAR pharmacophore modeling. Acta Pharmacol Sin. 2015; 36(8): 998-1012.

[17] Sawant RL, Ramdin SS, Wadekar JB. Synthesis, QSAR and docking studies of 5HT2Areceptor antagonising thiazolo[3,2-a]pyrimidines as antipsychotic agents.Marmara PharmJ. 2014;18(3): 109-119.

[18] Kumar R, Malla P, Verma A, Kumar M. Design of potent human steroid 5α-reductase inhibitors: 3D-QSAR CoMFA, CoMSIA and docking studies. Med Chem Res. 2013; 22(10): 4568-4582.

[19] Chaudhari RY, Bhise SB, Yadav A, Sonawane T. QSAR, Synthesis and Docking Study of 1, 4-DHP as Novel Antitubercular Agents. J Pharm Res Clin Pract. 2016;6(1): 1-9.

[20] Vasanthanathan P, Lakshmi M, Babu MA, Kaskhedikar SG. Classical QSAR study on chromene derivatives as lanosterol 14alpha- demethylase inhibitor: a non azole antifungal target. Med Chem. 2006; 2(4):363-367.

[21] Firoozpour L, Edraki N, Nakhjiri M,Emami S, Safavi M, Ardestani SK, Khoshneviszadeh M, Shafiee A, Foroumadi A.Cytotoxic activity evaluation and QSAR study of chromene-based chalcones. Arch Pharm Res.2012;35(12):2117- 2125.

[22] Consonni V, Ballabioand D, Todeschini R. Comments on the definition of the Q2 parameter for QSAR validation. J Chem Inf Model 2009; 49(7):1669-1678

[23] Consonni V, Ballabioand D, Todeschini R. Evaluation of model predictive ability by external validation techniques.J Chemometrics 2010; 24(3-4): 194-201.

[24] Lee PY, Chen CY. Toxicity and quantitative structure–activity relationships of benzoic acids to Pseudokirchneriella subcapitata. J Hazard Mater. 2009; 165(1-3): 156-161.

[25] Jing G, Zhou Z, Zhuo J. Quantitative structure-activity relationship (QSAR) study of toxicity of quaternary ammonium compounds on Chlorella pyrenoidosa and Scenedesmus quadricauda. Chemosphere 2012;86(1): 76-82.

[26] Shi LM, Fang H, Tomg W, Wu J, Perkins R, Blair RM, Branham WS, Dial SL, Moland CL, Sheenan DM. QSAR Models Using a Large Diverse Set of Estrogens. J Chem Inf Comput Sci. 2001; 41(1): 186–195.

[27] Hawkins DM. The Problem of Overfitting. J Chem Inf Comput Sci.2004; 44(1): 1–12.

[28] Consonni V, Ballabio D, Todeschini R. Evaluation of model predictive ability by external validation techniques. J Chemometrics.2010; 24(3-4):194–201.

[29] Wold S, Ericksson L. Partial least squares projections to latent structures (PLS) in chemistry. In Encyclopedia of computational chemistry, Ragu & Schleyer, P. (ed.), John Wiley & Sons, ltd. Chichester, 2002.

[30] VairaS, MantovaniVE, Robles JC, SanchisJC, GoicoecheaHC. Use of Chemometrics: Principal Component Analysis (PCA) and Principal Component Regression (PCR) for the Authentication of Orange Juice. J Anal Lett. 1999; 32(15): 3131-3141.

[31] Frisch MJ. Gaussian 03, Revision B, 01, Gaussian, Inc, Pittsburgh, PA. 2003.

[32] Parr R G, Pearson R G. Absolute hardness: companion parameter to absolute electronegativity. J Am Chem Soc. 1983; 105(26):7512-7516.

[33] Lee C, Yang Wand W, Parr RG. Development of the Colle-Salvetti correlation energy formula into a functional of the electron density. Phys Rev. B 1988; 37(2):785-789.

[34] Mushinski A, Nightingale MP. Many‐ body trial wave functions for atomic systems and ground states of small noble gas clusters. J Chem Phys. 1994; 101(5): 8831-8840.